| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |